2923674-83-1
Chemical Structure
PAV-104
Synonym(s): MAV-104
- CAS No.: 2923674-83-1
- Formula:C29H35N5O6S
- Molecular Weight:581.68
InChIKey: ICMWLGARAIHCPR-UHFFFAOYSA-N
SMILES: COC1=C(C=CC=C1CNC(C2=CC(C3CC3)=NN2C)=O)OCC4=CC=C(C=C4)C(N5CCN(CC5)S(C)(=O)=O)=O
Biological Activity: PAV-104 (MAV-104) is a host-targeted, pan-respiratory viral assembly inhibitor. PAV-104 targets a small subset of the host protein 14-3-3 within a transient multi-protein complex. PAV-104 inhibits SARS-CoV-2 replication by blocking post-entry viral assembly/budding through interaction with viral nucleocapsid (N) protein and interference with its oligomerization. PAV-104 is orally active in cats and shows favorable pharmacokinetic properties in rats. PAV-104 can be used for the study of COVID-19 and other respiratory viral infections, including Feline Infectious Peritonitis (FIP)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PAV-104 | 99.83% | PAV-104 (MAV-104) is a host-targeted, pan-respiratory viral assembly inhibitor. PAV-104 targets a small subset of the host protein 14-3-3 within a transient multi-protein complex. PAV-104 inhibits SARS-CoV-2 replication by blocking post-entry viral assembly/budding through interaction with viral nucleocapsid (N) protein and interference with its oligomerization. PAV-104 is orally active in cats and shows favorable pharmacokinetic properties in rats. PAV-104 can be used for the study of COVID-19 and other respiratory viral infections, including Feline Infectious Peritonitis (FIP). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Du L, et al. A viral assembly inhibitor blocks SARS-CoV-2 replication in airway epithelial cells. Commun Biol. 2024 Apr 22;7(1):486. [Content Brief]
- [2]. Michon M, et al. A pan-respiratory antiviral chemotype targeting a transient host multi-protein complex. Open Biol. 2024 Jun;14(6):230363. [Content Brief]
- [3]. Lingappa, et al. Evaluation of Safety and Pharmacokinetics for Orally Administered MAV-104 in Domestic Shorthair Cats. SSRN. November
